#Japan #Tokyo #Chronic Kidney Disease #Public Affairs

Introduction to CKD's Silent Threat

Chronic Kidney Disease (CKD), often referred to as the 'silent nation’s disease,' is a growing health issue that affects approximately 20 million individuals, or one in five adults in Japan. Tokyo, particularly, is identified as a high-risk area with the highest number of dialysis patients in the country, totaling approximately 33,462 individuals. This situation has led to massive financial strains on public health resources, with around ¥200 billion (approximately $1.8 billion) spent annually on dialysis care. The broader societal costs, including loss of labor and impacts on regional economies, may reach up to ¥344.4 billion (approximately $3 billion) per year. Clearly, CKD poses a significant threat to both the fiscal health of Tokyo and the overall sustainability of its society.

The Symptoms and Challenges of CKD

One of the defining characteristics of CKD is its progression without noticeable symptoms, which is why it is termed the 'silent disease.' Fortunately, recent advancements in medicine, including the introduction of SGLT2 inhibitors, mineralocorticoid receptor antagonists, and GLP-1 receptor agonists, promise to change the narrative. Early detection followed by intervention can potentially delay the onset of dialysis significantly.

However, despite these advancements, current screening methods such as urine protein testing (qualitative test) fail to identify early stages of kidney damage, particularly microalbuminuria, which is crucial for early intervention. As evidenced by data from 2025, the introduction of albuminuria testing (UACR) provides exceptional cost-effectiveness, which is a robust argument for implementing this test.

Disparities in CKD Responses Across Tokyo

Despite the available medical measures, there remains a stark disparity in CKD responses across Tokyo. In fact, of the 62 municipalities in Tokyo, only four have successfully implemented albuminuria testing. The existing approach, heavily weighted toward public awareness efforts, is severely lacking in systematic early detection and health care collaboration. The current strategies depend heavily on local enthusiasm and financial capacity, leading to significant inconsistencies in care and outcomes.

Proposed Comprehensive Tokyo Model

In light of these disparities, the Japan Public Affairs Association has issued a set of urgent recommendations structured as the "Tokyo Model." This model emphasizes four critical strategies: 1. Standardizing albuminuria testing in specific health examinations. 2. Introducing financial support unique to Tokyo to fill existing gaps in national systems. 3. Establishing clear patient pathways by visualizing CKD specialists and collaborating physicians. 4. Strengthening governance structures to promote comprehensive implementation across all health departments.

Adopting this model would not only safeguard the quality of life for Tokyo residents but also propel Japan’s CKD response initiatives forward. By placing health professionals at the forefront and ensuring systemic changes in care delivery, Tokyo has the opportunity to lead the national effort against CKD.

Collaborative Efforts and Future Initiatives

This policy proposal was authored with significant contributions from Dr. Koichi Okada, a professor in nephrology at Saitama Medical University. Bayer Pharmaceuticals has also endorsed this initiative, underscoring the shared commitment to address CKD’s pressing challenges. We extend our heartfelt gratitude to all individuals and organizations who supported this initiative.

Moving forward, our association prioritizes fostering open dialogues among citizens, policymakers, and government entities in a public affairs framework. Addressing complex societal issues, such as CKD, necessitates integrating the innovation and expertise of the private sector into viable solutions. Through ongoing discussions, research, and policy proposals, we aim to facilitate cooperative efforts to tackle this pressing health concern effectively.